Dermatologist told me to quit fin after turning 40 Finasteride/Dutasteride 10/19/2023
A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Sexual Dysfunction in Those with Androgenetic Alopecia on Dutasteride Versus Finasteride
Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.
community 31M. Just diagnosed with androgenic alopecia. Fears of min.
A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.
community Just to show you the superiority of dutasteride over finasteride (it's huge)
Dutasteride is shown to be significantly more effective than finasteride for treating male androgenic alopecia. Users discuss the difficulty of obtaining dutasteride in some countries and share personal experiences with its effectiveness and side effects.
community Why is no one talking about this? Topical dutasteride out performs oral finasteride.
Topical dutasteride is considered more effective for hair regrowth with fewer side effects than oral finasteride. Users have mixed experiences, with some preferring topical applications for reduced side effects.
community Female 37/F - On Meds, but no progress. Add PRP?
A 37-year-old woman with androgenetic alopecia is using spironolactone, oral and topical minoxidil, and considering PRP therapy due to lack of progress. She is unable to obtain finasteride, dutasteride, or bicalutamide and is exploring other options like Clascoterone and RU58841.
Related Research
6 / 6 results
research Androgenetic, Diffuse and Senescent Alopecia in Men: Practical Evaluation and Management
This review discusses the evaluation and management of male baldness and related conditions, but reports no new clinical results.
research Treatment options for alopecia: an update, looking to the future
This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.
research Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.
research ORAL AND TOPICAL FINASTERIDE IN THE TREATMENT OF MALE ANDROGENETIC ALOPECIA – NARRATIVE REVIEW
In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.
research The Challenging Consultation: Management of Melanoma
The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.